EC Number   |
Protein Variants |
Reference |
|---|
   3.4.24.B3 | A235P |
mutant shows about 10fold increased activity with alpha1-proteinase inhibitor |
652423 |
| 3.4.24.B3 | A235P |
site-directed mutagenesis, alters substrate specificity, mutant processed and truncated enzyme additionally cleaves casein, laminin, and type IV collagen, Ala 235 is typical for the enzyme and is located immediately after the Met-turn, which forms a catalytic basis for the zinc ion |
651851 |
| 3.4.24.B3 | A38V |
polymorphismsm rs738792, T/C, may be associated with Kawazaki disease in the Korean population |
709775 |
| 3.4.24.B3 | E216A |
active site mutant, catalytically inactive |
652423 |
| 3.4.24.B3 | E216A |
site-directed mutagenesis, exchange of a residue in the zinc-binding catalytic domain, inactive |
653398 |
| 3.4.24.B3 | E220A |
site-directed mutagenesis, exchange of a residue in the zinc-binding catalytic domain, inactive |
653398 |
| 3.4.24.B3 | more |
HLA-A2.1 transgenic mice are used to identify reactive epitopes as tools to assess immunogenicity in humans, identification of human MHC class I epitopes within human MMP11 |
708156 |
| 3.4.24.B3 | more |
HLA-A2.1 transgenic mice are used to identify reactive epitopes as tools to assess immunogenicity in humans, MMP11 vaccine in 1,2-dimethylhydrazine-colon cancer model, overview |
-, 708156 |
| 3.4.24.B3 | more |
mice lacking any one particular MMP, including ST3, often show little or weak phenotype |
707835 |
| 3.4.24.B3 | more |
MMP-11 genotyping, identification of single nucleotide polymorphisms |
709775 |
